In The Cancer Genome Atlas (TCGA) dataset, we discovered that larger cases of tumors with LADC had lower MALAT1 mRNA expression levels at pathologic stage (all LADC patients: p=0.0226; EGFR wild-type patients: p=0.0159) (Figure 1A), and lymph node metastasis (all LADC patients: p=0.0003; EGFR wild-type patients: p=0.0018) (Figure 1B) in all LADC (Total) or EGFR wild-type, respectively. Here, MALAT1 is linked to cancer.